全文获取类型
收费全文 | 69229篇 |
免费 | 4913篇 |
国内免费 | 2510篇 |
专业分类
耳鼻咽喉 | 310篇 |
儿科学 | 969篇 |
妇产科学 | 1059篇 |
基础医学 | 11782篇 |
口腔科学 | 957篇 |
临床医学 | 3873篇 |
内科学 | 11005篇 |
皮肤病学 | 1062篇 |
神经病学 | 10234篇 |
特种医学 | 836篇 |
外国民族医学 | 19篇 |
外科学 | 4157篇 |
综合类 | 7617篇 |
现状与发展 | 7篇 |
预防医学 | 1714篇 |
眼科学 | 600篇 |
药学 | 12947篇 |
6篇 | |
中国医学 | 1452篇 |
肿瘤学 | 6046篇 |
出版年
2024年 | 48篇 |
2023年 | 766篇 |
2022年 | 1064篇 |
2021年 | 2041篇 |
2020年 | 1778篇 |
2019年 | 1807篇 |
2018年 | 1889篇 |
2017年 | 1916篇 |
2016年 | 1986篇 |
2015年 | 2310篇 |
2014年 | 3812篇 |
2013年 | 5115篇 |
2012年 | 3799篇 |
2011年 | 4428篇 |
2010年 | 3643篇 |
2009年 | 3729篇 |
2008年 | 4060篇 |
2007年 | 3681篇 |
2006年 | 3221篇 |
2005年 | 2756篇 |
2004年 | 2611篇 |
2003年 | 2412篇 |
2002年 | 1924篇 |
2001年 | 1671篇 |
2000年 | 1530篇 |
1999年 | 1338篇 |
1998年 | 1515篇 |
1997年 | 1388篇 |
1996年 | 1076篇 |
1995年 | 1008篇 |
1994年 | 927篇 |
1993年 | 835篇 |
1992年 | 615篇 |
1991年 | 572篇 |
1990年 | 428篇 |
1989年 | 376篇 |
1988年 | 311篇 |
1987年 | 285篇 |
1986年 | 293篇 |
1985年 | 356篇 |
1984年 | 292篇 |
1983年 | 178篇 |
1982年 | 240篇 |
1981年 | 194篇 |
1980年 | 141篇 |
1979年 | 83篇 |
1978年 | 58篇 |
1977年 | 45篇 |
1976年 | 35篇 |
1975年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
61.
目的 观察重组人白介素-1受体拮抗剂(rhIL-1Ra)的毒性靶器官及毒性的严重程度.方法 32只成年恒河猴分为rhIL-1Ra 2mg/(kg·d)(n=6)、10mg/(kg·d)(n=6)和50mg/(kg·d)(n=6)连续给药90天组,10mg/(kg·d)(n=4)连续给药30天组,正常对照组(n=5)和溶剂对照组(n=5).rhIL-1Ra为皮下注射给药,每日1次.观察指标包括一般药物反应、尿八项、心电图、眼底检查、外周血细胞计数及白细胞分类、凝血时间、血清生化、外周血T细胞亚群和猴抗rhIL-1Ra抗体测定、脏器重量和脏器系数、常规病理组织学检查.结果 给药后30天各给药组动物血清非特异性抗体明显升高.rhIL-1Ra 2mg/(kg·d)组其他检测指标均未见明显地改变.rhIL-1Ra 10mg/(kg·d)组给药后90天肾小球毛细血管基底膜明显增厚,但此剂量给药时间为30天时未见任何异常.rhIL-1Ra 50mg/(kg·d)组肾小球及肾小管中蛋白性液体量多,小球毛细血管基底膜增厚更为严重,且停药30天后基底膜增厚程度仍未见明显减轻或改善.结论 rhIL-1Ra的主要毒性靶器官为肾脏,2mg/(kg·d)为安全剂量,10mg/(kg·d)给药30天时为安全剂量,给药90天为恒河猴中毒性剂量,而50mg/(kg·d)为明显的毒性反应剂量,可产生难以恢复的肾脏纤维化. 相似文献
62.
63.
W. S. L. Stebbings M. J. G. Farthing J. R. Puddefoot Elizabeth Anderson G. P. Vinson J. M. A. Northover R. F. M. Wood 《Journal of cancer research and clinical oncology》1988,114(2):208-211
Summary To evaluate the potential effect of androgens on the development and growth of human colorectal adenomas, the prevalence and concentration of cytosolic androgen receptors (AR) were analysed in 26 adenomas and 19 samples of normal colonic mucosa by a hybrid ligand receptor-binding assay. AR were detected in 7 of the adenomas (26.9%), and in 6 of the normal mucosa samples (31.6%). In the adenomas, AR levels demonstrated were low, ranging from 6 to 31 fmol/mg cytosol protein, and dissociation constants (Kds) ranged from 0.17–2.7x10-9
M. Of 13 adenomas excised from men, 6 (46%) had positive receptor activity, whereas only 1 of 13 (7.7%) from women was positive (P=0.03, Fisher's exact test). There was no correlation between AR titre and patient age, or between adenoma size and histological type or degree of dysplasia. In normal mucosa, AR levels ranged from 7 to 33 fmol/mg and Kds ranges from 0.24–3.1x10-9
M. There was no significant difference between either AR prevalence or levels in the adenomas and normal mucosa. The sex difference was exclusive to the adenoma. Endogenous androgen may play a role in adenoma development early in the promotional process. 相似文献
64.
65.
用放射配体结合分析法分别测定了正常组、特布他林组、特布他林十曲尼司特组豚鼠的肺组织β受体最大结合力和解离常数,结果显示:给特布他林后豚鼠肺组织β受体发生明显的向下调节.曲尼司特可预防此向下调节的发生. 相似文献
66.
P. A. Milligan P. E. McGill C. W. Howden A. W. Kelman B. Whiting 《European journal of clinical pharmacology》1993,45(6):507-512
Summary A randomised crossover study was performed in subjects with rheumatoid arthritis (or other arthropathies) to investigate if any alteration in the steady pharmacokinetics of the NSAID piroxicam (a drug which is extensively metabolised via cytochrome P450) or its major metabolites occurred as a result of coadministering either cimetidine or nizatidine.Twelve females and 2 males with mean age, weight, and albumin concentrations of 58 years, 61 kg, and 40 g·L–1 respectively, completed the study. Comparisons were made between the following parameters: plasma piroxicam AUCs [AUC0-24(P)], plasma 5-hydroxypiroxicam AUCs [AUC0-24(5-OHP)], the ratio of these i.e. AUC0-24(5-OHP):AUC0-24(p), the % piroxicam daily dose excreted in urine as 5-hydroxypiroxicam (before and after glucuronidase incubation); and the mean of the steady state trough piroxicam, and 5-hydroxypiroxicam concentrations (obtained during each study phase in addition to the wash-out period).A statistically significant difference as a result of initiating either cimetidine or nizatidine was obtained only for the ratio AUC0-23(5-OHP):AUC0-24(P). This was indicative of a weak potential to inhibit piroxicam hydroxylation.No clinically significant alteration in the steady state pharmacokinetics of piroxicam occurred in these subjects as a result of cimetidine or nizatidine coadministration. Consequently it is unlikely that any adverse events would arise from these combinations. 相似文献
67.
Summary— KR31080 (2-butyl-5-methyl-6-(1-oxopyridin-2-yl)-3-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-3H-imidazo[4,5-b] pyridine) is a potent inhibitor of angiotensin type 1 (AT1 ) receptors in rabbit aorta and human recombinant AT1 receptors. In the isolated rabbit thoracic aorta, KR31080 caused a nonparallel shift to the right of the concentration-response curves to angiotensin II (All) with decreased maximal response (pD'2 = 10.1 ± 0.1), but had no effect on the contractile response induced by norepinephrine. KR31080 inhibited specific [125 I]AII binding to rabbit aortic membranes (AT, receptors) and [125 I][Sar1 , Ile8 ]AII binding to human recombinant AT1 receptors in a concentration-dependent manner with IC50 values of 0.84 ± 0.08 nM and 1.92 ± 0.15 nM, respectively, but did not inhibit specific [125 I)AII binding to bovine cerebellum membranes (ÀT2 receptors). In the Scatchard analysis, KR31080 interacted with rabbit aortic AT1 receptors in a competitive manner, similar to losartan. These results demonstrate that KR31080 is a potent and AT1 selective angiotensin receptor antagonist which exerts a competitive antagonism in the [125 I]AII binding assay and insurmountable AT1 receptor antagonism in the functional study. 相似文献
68.
《中国药理学与毒理学杂志》1997,(1)
本实验探讨了内源性速激肽是否参与白三烯C4(LTC4)的气道效应.LTC4(0.5μgkg-1,iv)可增高豚鼠肺内压(IPP)和气道内依文思蓝渗出。速激肽NK-1受体拮抗剂CP-96345{(2S,3S)-顺式-2-(二苯甲基)-N-[(2-甲氧苯)-甲基]-1-杂氮双环[2.2.2]辛烷-3-胺}1mgkg-1,iv,可减弱LTC4诱导的依文思蓝渗出;NK-2受体拮抗剂SR-48968{(S)-N-甲基-N-[4-(4-乙酰氨基-4-苯基哌啶)-2-(3,4-二氯苯基)丁基]苯甲酰胺},1mgkg-1,iv,可抑制IPP的增高.白三烯拮抗剂ONO-1078(0.03mgkg-1,iv)可阻断这两种反应.结果说明内源性速激肽增强LTC4的气道作用,其中NK-1受体介导微血管渗漏,NK-2受体介导支气管收缩. 相似文献
69.
Serotonin (5-HT) is a mediator (through 5-HT1P receptors) of slow EPSPs in myenteric ganglia of the small intestine. The effect of 5-HT can be mimicked by elevating cAMP; therefore, we tested the hypothesis that the slow EPSP-like response to 5-HT is cAMP-mediated. Guinea pig gut was enzymatically dissociated; myenteric ganglia remained intact and were collected by filtration. Neurons in the isolated ganglia retained their ability to manifest the slow EPSP-like response to 5-HT. Exposure to 5-HT raised the ganglionic level of cAMP (ED50 0.3 μM). This effect was not antagonized by the 5-HT1P antagonist, N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide (100.0 μM), or mimicked by the 5-HT1P agonist, 5-hydroxyindalpine (10.0 μM). Increases in cAMP were also evoked by the 5-HT1 agonist, 5-carboxyamidotryptamine (10.0 μM), the 5-HT2 agonist, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 1.0–10.0 μM), and by the 5-HT4 agonists, renzapride (1.0–10.0 μM) and 5-methoxytryptamine (1.0–10.0 μM); however, neither the 5-HT1/5-HT2 antagonists, spiperone, methysergide, and methiothepin, nor the 5-HT4 antagonist, tropisetron (ICS 205–930; 10.0 μM), were able to inhibit the rise in cAMP evoked by these compounds or by 5-HT (0.1–10.0 μM). The 5-HT-evoked elevation of cAMP was antagonized by ketanserin (10.0 μM), which also blocked the effects of 5-methoxytryptamine and DOI, but not those of renzapride. The effective concentration of DOI, however, was higher than that needed for activation of 5-HT2 receptors, and Northern analysis using a cDNA probe encoding the rat 5-HT2 receptor failed to reveal the presence of 5-HT2 mRNA in myenteric ganglia, although it hybridizes with mRNA of the right size in the guinea pig brain. Compounds that failed to change levels of cAMP or to antagonize the action of 5-HT included 8-hydroxy-di-n-propylamino tetralin, R58639, R88226, and sumatriptan. It is concluded that the receptor responsible for the 5-HT-induced rise in cAMP in ganglia isolated from the guinea pig myenteric plexus is not a known subtype of 5-HT receptor. Since the pharmacology of this novel receptor is different from that of the slow EPSP-like response to 5-HT, the receptor probably does not mediate the slow EPSP. © 1993 Wiley-Liss, Inc. 相似文献
70.
目的研究不同剂量60Co γ射线辐照全血在保存期内红细胞CR1分子数目的变化.方法应用酶联法定量测定经15~35GY五个照射剂量辐照全血在保存期内红细胞CR1分子数目.结果照射后1d,15~25GY剂量组红细胞CR1分子数目相互间比较及分别与对照组比较无明显差异(P>0.05);经30、35GY辐照红细胞CR1分子数目分别与其他剂量组和对照组比较有明显差异(P<0.05~0.01).另外,随着保存期的延长,各剂量组和对照组红细胞CR1分子数目呈阶梯式下降,尤其在照射后3d,30和35GY剂量组红细胞CR1分子数目接近于照射后7d水平,二者相互比较无明显差异(P>0.05).结论在一定范围内(15~25GY)60Co γ射线剂量辐照对红细胞CR1分子数目无明显影响. 相似文献